Transsexualism - Diagnostic and therapeutic aspects

Endokrynologia Polska

Volumn 61, Issue 4, 2010, Pages 412-416

  Mȩdraś, Marek ^a,b   Jóźków, Paweł ^b  

^a UNIVERSITY OF WROC AW   (Poland)

^b UNIVERSITY SCHOOL OF PHYSICAL EDUCATION   (Poland)

Author keywords

Diagnosis; Gender identity disorder; Hormonal therapy; Transsexualism

Indexed keywords

ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; TESTOSTERONE; TESTOSTERONE ESTER;

DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC PROCEDURE; GENDER IDENTITY DISORDER; HEMATOCRIT; HORMONAL THERAPY; HUMAN; MONITORING; PROLACTINOMA; REVIEW; SIDE EFFECT; TRANSSEXUALISM; VENOUS THROMBOEMBOLISM;

EID: 77957265429     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Imieliński K. Zarys seksuologii i seksiatrii. Warszawa, PZWL 1982: 253.
2. van Kesteren PJ, Gooren LJ, Megens JA. An epidemiological and demographic study of transsexuals in The Netherlands. Arch Sex Behav 1996; 25: 589-600.
3. Veale JF. Prevalence of transsexualism among New Zealand passport holders. Aust N Z J Psychiatry 2008; 42: 887-889.
4. Korte A, Lehmkuhl U, Goecker D et al. Gender identity disorders in childhood and adolescence: currently debated concepts and treatment strategies. Dtsch Arztebl Int 2008; 105: 834-841.
5. Kipnis K, Diamond M. Pediatric ethics and the surgical assignment of sex. J Clin Ethics 1998; 9: 398-410. (Pubitemid 128688241)
6. Wallien MS, Swaab H, Cohen-Kettenis PT. Psychiatric comorbidity among children with gender identity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 1307-1314.
7. Reiner WG. Gender identity and sex-of-rearing in children with disorders of sexual differentiation. J Pediatr Endocrinol Metab 2005; 18: 549-553.
8. Hines M, Ahmed SF, Hughes IA. Psychological outcomes and gender-related development in complete androgen insensitivity syndrome. Arch Sex Behav 2003; 32: 93-101.
9. Wisniewski AB, Migeon CJ, Meyer-Bahlburg HF et al. Complete androgen insensitivity syndrome: long-term medical, surgical, and psychosexual outcome. J Clin Endocrinol Metab 2000; 85: 2664-2669.
10. Medras M, Szydlik H, Bulas Z et al. [Transsexualism as a congenital psychoendocrinological syndrome (in the light of 2 cases)]. Pol Tyg Lek 1982; 37: 59-61.
11. Cohen-Kettenis PT, van Goozen SH. Sex reassignment of adolescent transsexuals: a follow-up study. J Am Acad Child Adolesc Psychiatry 1997; 36: 263-271.
12. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94: 3132-3154.
13. Mueller A, Gooren L. Hormone-related tumors in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol 2008; 159: 197-202.
14. Baba T, Endo T, Honnma H et al. Association between polycystic ovary syndrome and female-to-male transsexuality. Hum Reprod 2007; 22: 1011-1016.
15. Gooren LJ, Giltay EJ. Review of studies of androgen treatment of female-to-male transsexuals: effects and risks of administration of androgens to females. J Sex Med. 2008; 5: 765-776.
16. van Kesteren PJ, Asscheman H, Megens JA et al. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf) 1997; 47: 337-342. (Pubitemid 27395966)
17. Toorians AW, Thomassen MC, Zweegman S et al. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab 2003; 88: 5723-5729.
18. Ott J, Kaufmann U, Bentz EK et al. Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy. Fertil Steril 2009.
19. Giltay EJ, Toorians AW, Sarabdjitsingh AR et al. Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-to-male transsexuals. J Endocrinol 2004; 180: 107-112.
20. Mueller A, Dittrich R, Binder H et al. High dose estrogen treatment increases bone mineral density in male-to-female transsexuals receiving gonadotropin-releasing hormone agonist in the absence of testosterone. Eur J Endocrinol 2005; 153: 107-113.
21. Jacobeit JW, Gooren LJ, Schulte HM. Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. Eur J Endocrinol 2009; 161: 795-798.
22. Serri O, Noiseux D, Robert F et al. Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient. J Clin Endocrinol Metab 1996; 81: 3177-3179. (Pubitemid 26296184)
23. Burcombe RJ, Makris A, Pittam M et al. Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual. Breast 2003; 12: 290-293.
24. Kuroda H, Ohnisi K, Sakamoto G et al. Clinicopathological study of breast tissue in female-to-male transsexuals. Surg Today 2008; 38: 1067-1071.
25. Dorff TB, Shazer RL, Nepomuceno EM et al. Successful treatment of metastatic androgen-independent prostate carcinoma in a transsexual patient. Clin Genitourin Cancer 2007; 5: 344-346.
26. Dizon DS, Tejada-Berges T, Koelliker S et al. Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecol Obstet Invest 2006; 62: 226-228.
27. Moore E, Wisniewski A, Dobs A. Endocrine treatment of transsexual people: a review of treatment regimens, outcomes, and adverse effects. J Clin Endocrinol Metab 2003; 88: 3467-3473. (Pubitemid 37034478)